Inhibitors of Protein Kinases and Protein Phosphates Contributors
暂无分享,去创建一个
L. Meijer | D. Fabbro | M. Yacoub | T. Meyer | D. Lawrence | D. Alexander | H. Hidaka | B. Druker | D. Fong | A. Berghuis | R. Engh | P. Furet | S. Kumar | M. Leost | C. Kunick | J. Griffin | M. Tremblay | G. Fendrich | P. Manley | D. Bossemeyer | D. Burk | L. Iversen | H. Andersen | V. Guez | O. Lozach | J. Mestan | A. Wakeling | H. Lyster | R. Battistutta | G. Zanotti | M. Gassel | S. Herrero | S. Sarno | S. Blake | C. Breitenlechner | R. Honkanen | S. Schmitt | M. Shibuya | Y. Suzuki | N. Banner | C. B. Jeppesen | C. Lampron | Y. Sasaki | N. Uetani | P. Cohen | A. Cheng | N. P. Møller | S. W. Cowan-Jakob
[1] M. Hatada,et al. X-Ray structure of citrate bound to Src SH2 leads to a high-affinity, bone-targeted Src SH2 inhibitor. , 2001, Journal of medicinal chemistry.
[2] K. Lam,et al. Discovery of a novel series of potent and selective substrate-based inhibitors of p60c-src protein tyrosine kinase: conformational and topographical constraints in peptide design. , 1998, Journal of medicinal chemistry.
[3] M. Inagaki,et al. Role of the pyrrolidine ring of proline in determining the substrate specificity of cdc2 kinase or cdk5. , 1997, Journal of Biochemistry (Tokyo).
[4] A. Wakeling. Discovery and Development of Iressa: The First in a New Class of Drugs Targeted at the Epidermal Growth Factor Receptor Tyrosine Kinase , 2005 .
[5] D. Alexander. Biological Validation of the CD45 Tyrosine Phosphatase as a Pharmaceutical Target , 2005 .